1. Home
  2. THRY vs BDTX Comparison

THRY vs BDTX Comparison

Compare THRY & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Thryv Holdings Inc.

THRY

Thryv Holdings Inc.

HOLD

Current Price

$3.72

Market Cap

170.3M

Sector

Industrials

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.99

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THRY
BDTX
Founded
2012
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.3M
171.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
THRY
BDTX
Price
$3.72
$1.99
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$9.33
$9.67
AVG Volume (30 Days)
917.2K
2.0M
Earning Date
04-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
100.50
130.71
EPS
0.10
N/A
Revenue
$785,015,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$38.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$1.93
52 Week High
$14.28
$4.94

Technical Indicators

Market Signals
Indicator
THRY
BDTX
Relative Strength Index (RSI) 51.35 35.86
Support Level $3.46 N/A
Resistance Level $4.17 $2.30
Average True Range (ATR) 0.29 0.30
MACD -0.01 -0.08
Stochastic Oscillator 43.32 0.75

Price Performance

Historical Comparison
THRY
BDTX

About THRY Thryv Holdings Inc.

Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: